$ABT

Morrone Louis H. sold $643K of ABT

Morrone Louis H. (EXECUTIVE VICE PRESIDENT) sold 5,850 shares of ABBOTT LABORATORIES (ABT) at $109.83 ($0.64M total) on 2026-08-11.

Original reporting
SEC EDGAR · Morrone Louis H.
Published Aug 13, 2026, 9:14 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 13, 2026, 9:45 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ABT
Neutral
medium confidence
Mentioned
$ABT
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ABTNeutralLow
01

Why it matters

The newest fact is the specific open-market sale details (shares, price, total value, and post-transaction holdings).

02

Market read

Traders may briefly watch for sentiment effects from insider selling, but there is no accompanying fundamental catalyst in the text.

03

What to watch

Insider sales can be driven by diversification, taxes, or pre-scheduled personal liquidity needs; the article provides no stated reason for the sale.

Relevance 5/10Novelty 3/10Timing: filed after-hours on 2026-08-13, covering a sale dated 2026-08-11

Background

The article is an SEC Form 4 insider transaction disclosure for Abbott Laboratories (ABT).

Company-level read

Ticker impact

$ABTNeutralMedium confidence
Context

Abbott Laboratories Form 4 shows EVP Morrone Louis H. sold 5,850 shares at $109.83 on 2026-08-11 for about $642.5K.

Expected impact

Low likelihood of a sustained price move; any near-term impact would be sentiment-driven and typically fades.

Evidence & confidence

The filing discloses transaction size, price, and post-sale holdings, but provides no new company-specific operational, financial, or regulatory information.

Market effects

No clear sector read-through; insider sales are common and not a sector catalyst by themselves.

None indicated.

None indicated.

Counterpoint

Because the filing states no pre-arranged 10b5-1 plan, some traders may interpret the sale as higher near-term risk, even though insider sales are often non-informational.

Key entities

  • Abbott Laboratories

    Subject of the Form 4 insider transaction disclosure.

  • Morrone Louis H.

    Executive Vice President who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ABTMedAI 8/10

NC reaches settlement with Abbott over contaminated baby formula that led to 2022 shortage

North Carolina settled with Abbott Laboratories for $384M over contaminated baby formula, part of a broader agreement with 39 states and the federal government. Abbott, which produces over 40% of U.S. formula, was accused of selling unsafe products and concealing test results. The recall caused a 2022 shortage. North Carolina's share is $216K, earmarked for Medicaid and nutrition programs.

$ABTHighAI 8/10

Abbott Laboratories To Pay $385M Over Allegations Of Tainted Infant Formula

Abbott Laboratories will pay $385M to resolve allegations of tainted infant formula. The settlement includes $348.7M to the federal government and $35.5M to state Medicaid programs. California's share is over $15M. The allegations span 2018-2022, involving production conditions that risked microorganism contamination. Abbott recalled several formula brands in 2022, leading to a nationwide shortage.

$ABTLowAI 8/10

Sunday Edition: Sodium

Abbott Laboratories agreed to pay $384.9M to settle a DOJ case over a 2022 infant formula outbreak. The settlement doesn't determine liability. Pending lawsuits remain. No specific company was named in an E. coli and Salmonella outbreak linked to seed supplier Everything Sprouts LLC. Italy's hepatitis A outbreak affected 130 people, possibly from bivalve mollusks. UK small businesses show good food safety practices but low awareness of food crime.

$ABTLow

State settles infant formula contamination lawsuit, more Health Headlines

Colorado will receive nearly $2 million from Abbott Laboratories as part of a $348 million settlement over allegations of misrepresenting the safety of its infant formula, with additional $35.5 million to be split among states. The lawsuit claimed Abbott failed to maintain safety standards and disclose contamination test results. The funds will be returned to Colorado's Medicaid program.

$ABTMedAI 8/10

Abbott Laboratories Pays 384 Million In Baby Formula Safety Settlement

Abbott Laboratories (ABT) will pay $384 million to settle a lawsuit alleging it failed to maintain safety standards in its baby formula manufacturing facilities from 2018 to 2022, according to New York Attorney General Letitia James. The settlement includes $348 million to the federal government and $35 million to a coalition of states, with New York receiving $9.3 million. The lawsuit claimed Abbott's practices put products at risk of contamination and misled safety inspectors.